BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO (berotralstat) Treatment

23.02.2024 - RESEARCH TRIANGLE PARK, N.C., Feb. 23, 2024 (GLOBE NEWSWIRE) - BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new analyses of real-world use of oral, once-daily ORLADEYO (berotralstat) that showed patients who initiated ORLADEYO ... Seite 1

Related Keywords

United States ,Bryan Arnold ,Jonathan Bernstein ,Bernstein Clinical Research Center ,University Of Cincinnati ,Bernstein Allergy Group ,Bernstein Clinical Research ,Rate Reduction After Beginning ,Multiple Patient ,Biocryst Pharmaceuticals Chart ,Iocryst Pharmaceuticals Kurs ,Iocryst Pharmaceuticals Aktie ,